[BIOSYNTHESIS OF FARNESOL PYROPHOSPHATE AND SQUALENE FROM 2-C14-MEVALONIC ACID BY CELL FRACTIONS OF ADRENAL HOMOGENATE].
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Urinary excretion of mevalonate was reported to be correlated with endogenous cholesterol biosynthesis. A method is described whereby mevalonate (MVA) concentration in urine is determined by bench top gas chromatography-mass spectrometry after extraction as mevalonalactone (MVL) and conversion to mevalonolactone mono-TMS derivative. Within- and between-assay coefficients of variation were 4.02% and 8%, respectively. The mean concentration of MVA in 24-h urine collections from ten normolipidemic urinary subjects was 203 +/- 49.6 ng/ml (range: 44-576 ng/ml). Administration of 40 mg of Pravastatin (an HMG-CoA reductase inhibitor) significantly decreased (approximately 50%) the night concentration of MVA in five healthy volunteers. This assay could be useful for investigation of endogenous cholesterol synthesis rate in various dyslipidemias and in response to drug treatment.
Studies on the synthesis of cholesterol with cell-free homogenates of liver from rats treated with graded doses of estrone show that, at doses of estrone which cause a reduction in blood cholesterol, there is an accompanying inhibition of cholesterol biosynthesis. Furthermore, this inhibition appears to occur at the stage of cholesterol biosynthesis at which mevalonate is decarboxylated.
The activity of mevalonate kinase and of mevalonate pyrophosphate decarboxylase in human skin fibroblasts grown in culture was increased when whole fetal calf serum in the incubation medium was replaced with lipid-deficient serum. The drug demecolcine interfered with low density lipoprotein binding by cells and increased sterol synthesis and activities of hydroxymethylglutaryl-CoA reductase and mevalonate kinase. In contrast to normal cells, fibroblasts from a patient with homozygous familial hypercholesterolemia did not show any lower mevalonate kinase activity following incubation with whole serum compared with that in cells incubated with lipid-deficient serum. Insulin increased the activity of mevalonate kinase in fibroblasts. Livers of rats fed for 7 days with a diet containing 1% cholesterol showed reduced activity of mevalonate kinase and mevalonate phosphate kinase. These results are consistent with the possibility that enzymatic reactions other than those catalyzed by hydroxymethylglutaryl-CoA reductase may play a role in the physiological regulation of sterol synthesis in mammalian tissues.
Explore the source record for details and available documents.